Shingles vaccines: real benefits, real risks.
Based on extensive analysis of clinical trials, post-market surveillance, and patient experiences, shingles vaccines do reduce net pain and suffering for most people - but with important nuances about side effects and individual variations.
Trial efficacy (Shingrix)
Experience Grade 3 reactions
Efficacy maintained at 11 years
Trial efficacy versus real-world performance.
Shingrix (Recombinant)
Demonstrated 97.2% efficacy in controlled trials but achieves 73.9-85.5% effectiveness in practice. Still impressive, but notably lower than marketing suggests.
Zostavax (Live Vaccine)
Showed 51% trial efficacy translating to approximately 48% real-world effectiveness, with dramatic age-related decline. Effectiveness plummets from 67% in year one to just 15% by year ten.
Durability Matters
Shingrix maintains approximately 80% efficacy through 11 years, while Zostavax effectiveness wanes dramatically. This fundamentally alters the risk-benefit calculation.
The reactogenicity reality.
17% of Shingrix recipients experience Grade 3 reactions - side effects severe enough to prevent normal activities. While most resolve within 2-3 days, documented cases reveal disturbing exceptions.
Persistent Symptoms
A 50-year-old woman with Crohn's disease developed persistent neurological symptoms lasting over 12 months. Multiple patient reports describe joint pain, fatigue, and neurological symptoms persisting for months.
Guillain-Barré Syndrome
Approximately 6 excess cases per million doses in adults 65+, prompting FDA-mandated warning labels in March 2021. While rare, GBS can cause permanent disability or death.
Post-Market Surveillance
66,849 adverse event reports for Shingrix through April 2024. Post-market data reveals side effects not fully captured in controlled clinical trials.
What "90% effective" actually means.
Number Needed to Vaccinate
- • 11-31 to prevent one shingles case
- • 261-350 to prevent one PHN case
- • 3.26% absolute risk reduction over 3.5 years
Baseline Risk Context
- • Age 50: ~6 cases per 1,000 person-years
- • Age 80: ~13 cases per 1,000 person-years
- • Lifetime risk: 30%, reaching 50% by age 85
For every 1,000 people aged 50+ vaccinated over 3.5 years, approximately 33 cases of shingles are prevented. Marketing claims require translation into these absolute terms.
Unexpected benefits and concerns.
Surprising Findings
- • 20% reduction in dementia diagnoses over 7 years (Stanford/Wales study)
- • 17% lower dementia risk with recombinant versus live vaccine
- • 23% reduction in cardiovascular events over 12 years
- • 16% reduction in COVID-19 infection, 32% reduced hospitalization
What This Might Mean
These "unexpected benefits" suggest the AS01 adjuvant may induce "trained immunity" - fundamental alterations to immune system behavior through epigenetic reprogramming. This could have both beneficial and harmful consequences not fully understood.
Natural strategies for prevention.
Lifestyle Pillars
- • 7-9 hours sleep, consistent bedtime
- • Stress management (high stress doubles risk)
- • 150+ min/week moderate exercise
- • Morning sunlight exposure
Nutritional Support
- • L-lysine (1-3g/day) - inhibits herpes replication
- • Limit high-arginine foods
- • Vitamin D through sunlight
- • Curcumin for anti-viral action
Individual risk assessment is crucial.
For most people 60+, vaccines demonstrably reduce net suffering. But patients deserve comprehensive information about both common reactions and rare serious events. If someone is able to restore their iodine and sunlight levels, the calculation may shift - this "virus" tends to show itself when we run out of light.